Close Menu

NEW YORK(GenomeWeb) – Researchers at Arizona State University's Biodesign Institute have identified an autoantibody signature that could prove useful in early detection of ovarian cancer.

Using high-density programmable protein microarrays, they identified autoantibodies to 12 protein antigens that could distinguish between ovarian cancer samples and controls. These markers are now being tested further through the National Cancer Institute's Early Detection Research Network, Karen Anderson, an ASU researcher and one of the leaders of the effort, told GenomeWeb.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.

Aug
22
Sponsored by
BC Platforms

This webinar will discuss how the Estonian Biobank, a cohort of more than 165,000 participants, is addressing industry challenges with data management and collaboration in the transition to precision medicine.

Oct
23
Sponsored by
Swift Biosciences

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries.